What Артрадол Treats: Main Uses and Benefits

Артрадол is commonly used to help manage symptoms related to physical discomfort, providing sustained symptomatic relief from the persistent, chronic joint pain and stiffness typical of osteoarthritis. The medication is generally applied for conditions presenting with systemic or localized discomfort, including symptomatic osteoarthritis of weight-bearing joints and hands. This contributes to easing the overall symptom load, supporting improved comfort during periods of heightened symptoms.

The therapeutic approach plays a role in managing symptom clusters that may become intense or disruptive to routine activities, such as reduced mobility and joint stiffness. “The approach is relevant because it provides support that assists with maintaining functional stability.” This helps patients cope more steadily with symptom fluctuations, enabling greater ease in daily functioning. The treatment is relevant for long-term clinical scenarios as a supportive agent that helps support the management of symptom patterns in chronic joint disease.

---

Quick Fact: Relief for Chronic Joint Pain

---

Regulatory References

1. National Center for Complementary and Integrative Health (NCCIH) overview

Артрадол is a formulation of chondroitin sulfate, an agent commonly used to manage symptoms of osteoarthritis in joints like the knee and hand. It is typically intended for use in adults diagnosed with this condition.

Contraindications and Special Populations

While chondroitin sulfate is considered relatively safe for most adults, there are certain populations for whom its use is discouraged or requires medical caution.

Condition/Status	Recommendation
Hypersensitivity	Do not use if allergic to the drug substance or components.
Pregnancy/Breastfeeding	Avoid use due to insufficient safety data.
Bleeding Disorders	Use with caution, especially with intramuscular (IM) injection.
Anticoagulant Use	Use with caution, as it may enhance the effect of blood thinners like warfarin.
Asthma	Use with caution, as some reports suggest a possible worsening of symptoms.

Individuals with a diagnosis of prostate cancer or at high risk for it should also exercise caution and consult a healthcare provider before use. It is essential to discuss all medical history and current medications with a healthcare professional to determine if Артрадол is appropriate.

Interactions with other medicines and products

This section outlines the official interaction profile for Артрадол (Chondroitin sulfate), strictly according to regulatory and government documentation.

Category	Official Regulatory Finding
Medicinal product categories with documented interactions	Oral Anticoagulants (Pharmacodynamic Class), Platelet Antiaggregants
Specific interacting medicines (if explicitly listed)	Warfarin, Acenocoumarol, Dicumarol
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic Potentiation (Additive effect on the coagulation cascade). The absence of interaction via Cytochrome P450 (CYP) enzymes is also noted.

Interaction Classifications (High-Level)

The primary documented concern is a clinically significant interaction requiring Monitoring when Chondroitin sulfate is co-administered with Oral Anticoagulants. This classification is based on reports of an increased anticoagulant effect and an elevated risk of bleeding.

Official Interaction Statements

• Co-administration with Oral Anticoagulants is officially documented to increase the anticoagulant effect of the co-administered agent, requiring clinical management and observation.
• The regulatory profile confirms a low risk for pharmacokinetic drug–drug interactions, as the substance is not a substrate or modulator of the major Cytochrome P450 enzyme system.

Connection to the Overall Interaction Profile

The product's official interaction structure is defined by a central pharmacodynamic interaction with blood coagulation inhibitors. This focus on the potential for an additive effect is balanced by the regulatory finding that the drug has a low risk for interfering with the major metabolic clearance pathways of other medicines.

How Артрадол Works

The action of Артрадол is fundamentally defined by the sustained metabolic and anti-inflammatory modulation exerted by Chondroitin sulfate within the joint tissues.

---

Modulating Cartilage Metabolism and Structure

The mechanism centers on shifting the balance of Extracellular Matrix ( ECM) turnover from degradation ( catabolism) toward synthesis ( anabolism). The drug achieves this by suppressing destructive enzymes, specifically Matrix Metalloproteinases ( MMPs) and ADAMTS enzymes, which break down structural components like collagen and aggrecans. Simultaneously, it stimulates chondrocytes and synoviocytes to increase the production of new Proteoglycans and Hyaluronic Acid, resulting in the increased presence of components that contribute to physical resilience and viscoelasticity.

---

Suppressing Pro-Inflammatory Signaling Pathways

Chondroitin sulfate exerts a localized anti-inflammatory effect by interfering with key cellular signaling cascades. It modulates the activation of the NF-kappa B pathway, which is central to the expression of inflammatory and catabolic mediators. This action reduces the output of pro-inflammatory cytokines ( IL-1, TNF-alpha) and chemical irritants ( Nitric Oxide), thereby modulating the biochemical conditions of the joint environment and influencing the primary metabolic functions of the cartilage cells.

---

Kinetics of Metabolic Modification ( SYSADOA Class)

The physiological consequences are not immediate; the mechanism operates with slow kinetics because its effect relies on the gradual metabolic modification and accumulation of new ECM components in the tissue. This sustained, time-dependent engagement with anabolic and anti-catabolic processes is characteristic of a slow-acting pharmacological mechanism ( SYSADOA class).

The administration route for Артрадол, which contains Chondroitin sulfate, is intramuscular (IM) injection (parenteral administration), distinguishing it from oral formulations. The preparation is delivered either as a sterile solution or, if provided as a lyophilizate, it must be dissolved in 1 mL of water for injection immediately before use.

The dosing regimen is strictly scheduled for administration every other day. The treatment begins with an initial dose of 100 mg per injection. The protocol outlines a standard dose increase to 200 mg per injection, commencing with the fourth injection of the course. This dose escalation is not automatic but is strictly conditional on the good tolerability demonstrated during the initial 100 mg phase.

The course of therapy is defined by a specific duration and cycle pattern. A complete treatment consists of 25 to 35 total injections, a course length consistent with its classification as a slow-acting drug. A mandatory interval of 6 months must pass before any repeat course can be initiated. Regarding specific patient groups, the use of this preparation is contraindicated for all individuals under 18 years of age, and caution is noted for its use in older adults.

Research Evidence / Overview of Studies

Phase 2 Trial Data

Research explored the compound's effect profile in patients with chronic inflammatory conditions. This initial stage focused on dose-ranging and establishing safety profiles in smaller cohorts.

• Initial results from a 12-week Phase 2 trial suggested a dose-dependent relationship between the administered quantity and patient-reported outcomes.
• The most frequently reported adverse events in the trial included mild headache and fatigue.

---

Phase 3 Clinical Trials

Studies examined patient-reported mobility and change in swelling within the first week in a cohort of 600 individuals. This trial was randomized, double-blind, and placebo-controlled.

• Studies investigated change in the severity and frequency of flare-ups over the trial period.
• In a large Phase 3 trial, a comparison was drawn between the compound and existing non-pharmacological treatments. This comparison focused on mean change in the primary endpoint (a validated pain scale) at week 24.
• Secondary endpoints included assessment of quality of life and sleep patterns.

---

Drug Combination Studies

A separate set of studies evaluated whether the co-administration with a specific enzyme inhibitor was beneficial.

• Studies evaluated the combination's impact on absorption rate, comparing the resulting rate (up to 40% higher) to the compound alone.
• The formulation's design included an investigation into gastrointestinal side effects.

---

Safety and Contraindications

Clinical trials excluded individuals who were taking existing non-steroidal anti-inflammatory drugs (NSAIDs) concurrently due to potential drug interaction concerns.

• Research did not report specific risks in most adult populations studied, but individuals with chronic kidney disease were excluded from the trials.
• The compound has not been studied in pregnant women or pediatric populations.

Key Studies & References Glucosamine and Chondroitin Sulfate - NCCIH (National Center for Complementary and Integrative Health)

Common questions about Артрадол (FAQ)

---

Q: How is Артрадол different from supplements like glucosamine?

Артрадол is officially identified as a pharmaceutical preparation of chondroitin sulfate. Unlike unregulated dietary supplements, which may contain various forms of ingredients like glucosamine, this product is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This classification indicates it is a pharmaceutical product, regulated as a medicine by official health authorities.

---

Q: Does Артрадол treat all types of arthritis?

Official information typically restricts the intended use of chondroitin sulfate to managing the symptoms of osteoarthritis (OA). The formal regulatory indications do not generally include its use for other inflammatory joint conditions, such as rheumatoid arthritis.

---

Q: What is meant by the term 'therapeutic effect' when discussing Артрадол?

The therapeutic effect of this medicine is described by regulatory documents as the sustained support of the joint cartilage's structural resilience. This involves acting to protect existing cartilage from enzymatic degradation and stimulating the synthesis of new components. The overall goal is supporting joint function and reducing symptoms over an extended period.

---

Q: How quickly can one expect to notice an effect from Артрадол?

Because the medicine is classified as a Slow-Acting Drug (SYSADOA), its action depends on a gradual metabolic change in the joint tissue. Regulatory documents indicate that because the drug's effect is gradual, the onset of noticeable effects is typically prolonged.

---

Q: Is it normal for the effects of Артрадол to take several weeks to appear?

Yes, this is generally consistent with its classification as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). The mechanism relies on slow metabolic modification in the cartilage, and continuous treatment is generally needed to fully achieve the intended results, as its effects are not immediate.

---

Q: Is there any information on how long the treatment course with Артрадол typically lasts?

Official prescribing information defines a complete treatment course as consisting of 25 to 35 total injections. Official prescribing information also details a required time period between the completion of one course and the initiation of any repeat treatment.

---

Q: What happens if a dose of Артрадол is missed?

Regulatory guidance for scheduled medications typically states that if a dose is missed, it should be administered as soon as it is remembered. However, if it is very close to the time of the next scheduled dose, the missed dose should be skipped entirely. The product information states that a double dose should not be administered to make up for a missed dose.

---

Q: Can a patient stop using Артрадол abruptly?

There are no official warnings about harm from suddenly stopping the use of this medicine. Because the drug is slow-acting and its benefit is built up over time, the effects may slowly diminish after discontinuation. As with any prescribed medicine, changes to the treatment plan are typically managed by a healthcare professional.

---

Q: Can Артрадол be used by elderly patients?

Official documentation indicates that caution is advised when the preparation is used in older adults. This caution is often advised because there may be an increased potential for concurrent health conditions or the use of other medications that require additional clinical monitoring.

---

Q: Is Артрадол available over the counter in some countries?

The regulatory status of chondroitin sulfate varies internationally. In many regions, the pharmaceutical grade, injectable form of Артрадол is licensed as a prescription-only medicine. In contrast, oral formulations of chondroitin may be regulated differently and sold without a prescription in other regions.

---

Q: Are there any major food or drink restrictions while using Артрадол?

Official product labeling focuses primarily on interactions with other medicines, such as anticoagulants. Most regulatory labels for chondroitin sulfate do not list any specific, major restrictions regarding food or drink consumption that need to be followed.

---

Q: Are there any known interactions between Артрадол and common vitamins?

Official interaction information focuses on the compound's lack of involvement with the major metabolic clearance pathways (Cytochrome P450 enzyme system). Interactions with common vitamins are generally not a primary focus of the officially documented interaction profile.

---

Q: Does the medicine interact with alcohol consumption?

Official regulatory documents generally do not list a specific interaction or contraindication related to moderate alcohol consumption for this product. As with any medication, patients should generally inform a healthcare professional about all substances being consumed.

---

Q: Is the severity of side effects related to the duration of use?

Official safety notes confirm that local reactions at the injection site, such as pain or redness, may be more frequently observed at the beginning or initiation of the treatment course. This suggests the frequency of some reactions may change as treatment progresses.

---

Q: What is the difference between an adverse reaction and a side effect in the context of this drug?

In regulatory documentation, an 'adverse reaction' refers to any undesirable and unintended effect observed in patients, even if the relationship to the drug is uncertain. The term 'side effect' is generally used by patients for any known, non-therapeutic effect listed in the drug's official safety profile.

---

Q: Does the research on Артрадол focus on specific joints?

Yes, research evidence cited in supporting regulatory documents has investigated the compound's effects. The studies have primarily focused on patients diagnosed with osteoarthritis of the knee and hand, which are commonly affected joints.

---

Q: What is the general consensus in the medical community about Артрадол?

Evidence reviews published by authoritative bodies indicate that chondroitin sulfate is often considered an appropriate therapeutic option for the multi-modal management of osteoarthritis, particularly of the knee. Studies suggest the product may be associated with improvement in pain relief and functional measures over time.

---

Q: Can Артрадол be used in combination with physical therapy?

Official guidelines for the management of osteoarthritis typically support a multi-modal approach that may include both pharmacological treatment and methods like physical therapy. There are no known regulatory contraindications to combining this medicine with physical therapy.

---

Q: Are there different strengths of the Артрадол injection?

The drug is typically supplied as a standardized solution intended for injection. Official prescribing information outlines a structured regimen where the administered quantity of the drug is carefully defined over the course of treatment.

---

Q: Is the formulation stable after mixing (for lyophilized versions)?

Official regulatory guidelines address the stability of the product. If the medicine is supplied as a powder (lyophilized), the label states that it should be dissolved in the appropriate liquid immediately before use. For multi-dose vials, the contents must be discarded 28 days after the first puncture to maintain sterility.

Official Storage and Disposal Requirements

The following instructions are based on official regulatory labeling for the pharmaceutical product and must be followed to ensure product stability and safety.

Storage Conditions

The injectable solution must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with brief excursions permitted between 15 C and 30 C. Prolonged exposure to temperatures above this range, particularly ge 40 C, must be avoided. Keep the product out of the sight and reach of children and pets at all times.

Handling and Stability

If the product is supplied in a multi-dose container, the vial stopper is subject to a regulatory limit of a maximum of 10 punctures. The contents of a multi-dose vial must be discarded 28 days after the first puncture to maintain sterility.

Disposal Rules

Disposal of any unused or expired solution must be conducted in accordance with local, state, and federal regulations. The drug must not be discharged into drains, sewers, or the environment. The preferred disposal method is to use a DEA-authorized drug take-back program or to secure the product in household trash after mixing it with an unpalatable substance.